Privately-held British drugmaker Mundipharma has secured European approval for Rezzayo (rezafungin), for the treatment of invasive candidiasis in adults.
The decision is based on results from the Phase III ReSTORE trial, which demonstrated statistical non-inferiority compared to the current standard of care, caspofungin.
Invasive candidiasis is a severe, life-threatening infection affecting seriously ill people, especially those with a weakened immune system.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze